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Background. Catheter-related infections, thrombosis, and stenosis are among the most frequent complications associated with
catheters, which are inserted in vessels. Surface treatment processes of the outer surface, such as ion-beam-assisted deposition, can
be used to mitigate such complications. Methods. This retrospective study (1992–2007) evaluated silver-coated (54 patients) and
noncoated (105 patients) implanted large-bore catheters used for extracorporeal detoxiﬁcation. The catheters were inserted into
the internal jugular or subclavian veins. After removal, the catheters were cultured for bacterial colonization using standard micro-
biologic assays. They also were examined using scanning electron microscope. Results. The silver coated catheters showed a ten-
dency towards longer in situ time. The microbiologic examinations of the catheter tips were in both catheter types high positive,
but not signiﬁcant. Conclusion. The silver-coated catheters showed no signiﬁcantly reduction in infection rate by evaluation of all
collecteddatainthisretrospectivestudy.Therewasnoassociationbetweenbothcathetersinsigniﬁcantlyreducingsavingsintreat-
ment costs and in reducing patient discomfort. Other new developed catheter materials such as the microdomain-structured inner
and outer surface are considered more biocompatible because they mimic the structure of natural biological surface.
1.Introduction
Since the introduction of large-bore catheters for acute
hemodialysis more than 50 years ago [1, 2], many problems
with handling, materials, and contamination of these cathe-
ters have arisen. Catheterization of the femoral vessels pro-
duces more complications than the catheterization of the
superior vena cava (SVC). Cannulation of the SVC versus the
subclavian vein is diﬃcult to implement and involves a
higher complication rate [2, 3]. Using the infraclavicular
catheterization technique, it is often diﬃcult to push the
large-bore catheter under the clavicle. Because of the anato-
mical position of the subclavian vein, perforation is more
likely with a rigid, large-bore catheter, apart from the danger
of causing a pneumothorax or a hemothorax [3–9].
Despite technical innovations in hemodialysis (HD) and
apheresis, the problems of providing temporary or perma-
nent vascular access appear to have found no satisfactory
solution. Temporary vascular access, in particular, still pre-
sents considerable problems. Therefore, many investigators
have inserted large-bore catheters in the superior vena cava
rather than in the internal jugular or the subclavian veins [3–
9]. Dialysis catheters are used for vascular access in 65% of
incident hemodialysis patients, and in 25% of the prevalent
HD populations [10]. Complication rates due to infections
for venous catheters are reported to be between 34 and 40%
and more [11, 12].
Synthetic catheter implants are increasingly used for in-
tensive medical treatment and extracorporeal detoxiﬁcations
procedures. Correspondingly, typical complications such as
infections and thrombosis have also increased. Infections
present a particular problem because they can appear at any
time, even years after an implantation, and may aﬀect all
materials.
Catheter-related bacteremia is a major cause of morbid-
ity among hemodialysis patients. Treatment with systemic2 International Journal of Nephrology
antibioticsalonewithoutremovalofthecatheterfailstodeﬁ-
nitively eradicate the infection in most patients [13]. Cath-
eter-related bacteremia can be managed by either catheter
removal with delayed placement of a new catheter or ex-
change of the infected catheter with a new catheter over a
guide-wire and additional systemic antibiotic therapy.
The source of catheter-related bacteremia is in most
patients a bacterial bioﬁlm, which forms in the catheter
lumen. This bioﬁlm, mostly consisting of Staphylococcus
aureus, cannot be destroyed or eliminated by a systemic anti-
biotic therapy because of antimicrobial resistance [14].
In 1981, Locci et al. demonstrated that bacterial could
most of the time colonize artiﬁcial, rough surfaces [15]. The
combination of tough surfaces and protein deposits should
beanidealsituationforthecolonizationofbacteria.Thebac-
teria could produce and become covered with a slime layer,
in which case antibiotic drugs have no inﬂuence on the bac-
teria. The bacteria under the slime layer use the organic sub-
stances of the catheter material for their metabolism. The
toxins of the bacteria can penetrate the slime layer and enter
the patient blood provoking a catheter infection. Bioﬁlm is
a microbial-derived sessile community characterized by cells
that are irreversibly attached to a substratum or to interface
to each other, embedded in a matrix of extracellular poly-
mericsubstancesthathaveproduced[16].Suchabioﬁlmcan
be the origin of ﬁbrin sheath formations leading to cathe-
ter dysfunction due to blood ﬂow reducing and to blood dis-
turbances. The therapy must be to remove the catheter im-
mediately or exchange it over a guide-wire with a new cathe-
ter and additional systemic antibiotic therapy.
In addition to infection, biocompatibility of synthetic
materials is a major problem. The interaction of blood with
a synthetic surface causes coagulation and activation of the
complement system. This can lead to the adsorption of var-
ious proteins and the formation of a layer of protein on the
synthetic surface. Thrombocytes, other cells, and bacteria
adhere to this layer of protein so that thrombi may form,
which can lead to blood ﬂow disturbances and catheter dys-
function [17]. Because of these problems, surface modiﬁca-
tion processes that can reduce the rate of infection or throm-
bogenicity, without adversely aﬀecting basic catheter design
and functionality, are of special interest.
The large-bore catheter has been frequently modiﬁed
over recent years, and all models available are of similar con-
struction with single, double, or triple lumen [18–25]. To
inﬂuence catheter-related bacteremia, diﬀerent new develop-
ments are available today, like coating of the catheter surface
with antibiotic-heparin, cuﬀs on the outer surface, catheter
for tunnelling, installation of an antibiotic-anticoagulant
lock into the catheter lumen after the HD, and so forth, [13,
26, 27].
The authors introduced in 1979 the transcutaneous
insertion of large-bore catheters through the internal jugular
vein [11], and in 1992 they used for the ﬁrst time available
catheters which were coated on the outer surface with silver.
In a retrospective study from 1992 to 2007, all catheters
with surface treatment of silver versus untreated catheters
were investigated after removal using a scanning electron
microscope. Also, bacterial colonization and thrombus accu-
mulationandthecuﬀsofthecathetersafterﬁxationwerealso
investigated. In a preliminary study from 2001, the authors
found a decline of the infection rate with the surface-treated
catheter [28]. To examine these results in a 15-year study is
the aim of this paper.
2. Catheter andMaterial
Most of the available single-, double- or triple-lumen cathe-
ters have some deﬁciencies depending on the material. Not
all catheters are radiopaque. No problem is experienced with
polyurethane catheters after the incorporation of contrast
media; however, the latter material may aﬀect catheter dura-
bility when using Teﬂon. This problem was overcome by
making a thicker catheter wall, but this caused endothelial
irritation and early thrombus formation. Catheters provid-
ing radio contrast are not absolutely necessary, however,
because their position can be controlled more simply and
gently with an intra-atrial electrocardiogram lead (ia ECG)
[29]. The three most important criteria of any catheter mate-
rial are a good tolerance, a low thrombogenicity, and a low
infection rate [30, 31].
Rarely do the material properties perfectly match every
r e q u i r e m e n ti nag i v e na p p l i c a t i o na n db i o m a t e r i a l sa r en o
exception. For instance, although a candidate orthopedic
material may have ideal mechanical properties, it may elicit
a deleterious biological response, or a candidate biosensor
withgoodelectricalcharacteristicsmaycorrodereadilyinthe
presence of body ﬂuids [32]. Therefore, it often becomes
necessarytostrikeacompromisesothatamaterialhasaccep-
table properties in each pertinent area. This compromise is
often made between bulk and surface properties. For exam-
ple, in a product such as a hemodialysis catheter, which
demands both good ﬂexibility and low surface friction, the
best candidate may be a slippery, less ﬂexible material rather
than a more supple one with unacceptably high friction.
A wide spectrum of biomaterial surface properties,
including biological, mechanical, chemical, and other prop-
erties that directly inﬂuence biocompatibility and functio-
nality, can be modiﬁed. Surface engineering is generally con-
sidered when a “good” surface is not good enough, when
devices would not function without it, or when product dif-
ferentiation is desired [32].
The importance of surface-engineered biomaterials has
beenrecognizedbymajormedicaldevicecompanies,because
surface modiﬁcation processes can reduce the rate of infec-
tion, thrombogenicity, and other catheter-related complica-
tions without adversely aﬀecting the basic design function of
catheters.
Although the ﬁeld is still essentially in its infancy, the
r a n g eo fs e r v i c e sc u r r e n t l yo ﬀered by surface treatment ven-
dors is varied and continually expanding. Examples include
conventional coating process such as depending and spray-
ing, vacuum-deposition techniques (e.g., sputtering), and
surfacemodiﬁcationapproachessuchasdiﬀusion(nitriding,
carburizing), laser and plasma processes, chemical plating,
grafting or bonding, and bombardment with energetic par-
ticles (as in plasma immersion or ion implantation). Of theInternational Journal of Nephrology 3
Table 1: Characteristics of 159 patients who received large-bore
catheters for dialysis or apheresis.
Parameter Mean ± SD
Age (30–82 years) 66.5 ±13.2
Females (n (%)) 94 (59%)
Treated surface catheters (silver) (n (%)) 54 (34%)
In situ time (days) 217.6 ±285.8
(Median 123.0, 1–1845)
Treatments (n) (dialysis, apheresis) 76.4 ±103.4
(Median 44.0, 1–670)
available techniques, those based on ionised particle bom-
bardment have been particularly successful in biomaterial
surface modiﬁcation, primarily because they combine versa-
tility and low-temperature processing with superior process
control, reliability, and reproducibility [32].
The ion-beam-based technology used for the treatment
of catheters covered herein is ion-beam-assisted deposition
(IBAD; Spi-Argent, Spire Corporation, Bedford, MA, USA)
[33–35]. The process is typically performed at low temper-
ature under high vacuum. The aﬀected layer in the typical
ﬁlms deposited by the IBAD process is in the order of 1μm
or less, so vacuum-compatible catheter materials may, there-
fore, be treated without adversely aﬀecting bulk mechanical
properties. The IBAD is line-of-sight process. This implies
that only the outer surface of the catheters can be treated
directly; however, parts with complicated geometries may be
manipulated for uniform coverage of all surfaces. The ion-
beam-assisted deposition of a silver coating was used [36].
Silver has been indicated as a good prospect for an infec-
tion-resistant coating material for catheters. The problem
previously preventing the use of silver on catheters has been
the inability to deposit adherent ﬁlms of silver on ﬂexible
polymeric substrates. The IBAD process permits the forma-
tion of silver coatings at a relatively low temperature with
extremely good adhesion that prevents delamination of the
ﬁlm during extended exposure to bodily ﬂuids. The IBAD
silver-depositedﬁlmhasalowcoeﬃcientoffriction,ishighly
uniform, and has demonstrated excellent adhesion. Biocom-
patibility testing consisted of a cytotoxicity test, and the USP
Systemic Injection Test. Excellent results were obtained in
both tests [32, 36–38].
3. Patients
The authors present the retrospective study from 1992 to
2007; the inclusion criteria were patients >18 years of age
who requires a large-bore catheters (in-/outpatient), were
free of bacteremia, and provided informed consent. The exc-
lusion criteria were a pregnant or lactating female, a hyper-
sensitivity of silver, and a bacteremia at the time of catheter
insertion. An IRB approval was in 1992 not necessary.
In the study, a total of 159 patients (age 66.5±13.2y e a r s ,
females n = 94 (59%) are involved (Table 1)). Large-bore,
single lumen catheters were inserted percutaneously in the
internal jugular or subclavian veins. The percutaneously
catheterisationwasnecessaryinrenalfailurebecauseofacute
kidney injury (AKI) for hemodialysis due to cardiovascular
disease, postoperative AKI, and so forth, and in end-stage
renal disease (ESRD) because of clotting ﬁstula, septicemia,
abscess and catheter thrombosis, and faults in the catheter
material (n = 138 (86.8%)) (Table 2). Further indications to
catheterisationwereaccessproblemsinpatients withfamilial
hypercholesterolemia (n = 12 (7.5%)), diﬀerent indications
for plasmapheresis (n = 7 (4.4%)), and in 2 patients with
carcinoma (n = 2 (1.3%)).
In 54 patients (34%), a catheter with a silver coating on
the outer surface (Spi-Argent, Spire, Bedford, MA, USA) was
inserted, and 105 patients (66%) received untreated cathe-
ters. Patients with untreated catheters were younger (62.2 ±
16.2v e r s u s6 8 .8 ± 10.7, P = 0.003), but there were no dif-
ferences between the groups regarding gender distribution,
diagnosis, or extracorporeal detoxiﬁcation methods. The
catheters were placed by nephrologists after the Seldinger
technique and/or under ﬂuoroscopic guidance. Before per-
cutaneousinsertion,eachpatientskinwasdisinfectedusinga
consistent method, and a sterile skin smear was taken for
microbiologic examination, and then the catheter was inser-
ted. Before ﬁxing the catheter with a suture, its position (par-
ticularly the catheter tip) should be checked with a normal
radiological control and/or with an ia ECG [29]. In long-
term catheters, a blood smear was taken every 4 weeks to
screen for bacteria. Catheters were removed either when
othervascularaccessroutesbecameavailableorwhenserious
infections developed, or if the catheter was not longer neces-
sary.
Before catheter removal, a skin smear was taken. The
catheters were then removed under sterile conditions, and
the tip was examined bacteriologically. In the remainder, the
catheter was rinsed in a physiological saline solution and
ﬁxed in a solution of phosphate buﬀer containing glutaralde-
hyde and formaldehyde for histological investigation.
4.StatisticalAnalysis
Statistical analysis was performed using the Statistical Pack-
age for Social Sciences (SPSS 13.0). All continuous data are
presented as mean ± standard deviation (SD) or if the data
showednonormaldistribution,asmedianandrange.Dicho-
tomous data were presented as a number (n)o ri np e r c e n t
(%). Univariate, unadjusted analyses were performed with
the independent samples t-test, chi-square test, Fisher’s exact
test for frequencies at or below 5, and the Wilcoxon’s rank
sum test. Pearson’s correlation coeﬃcient was calculated and
multivariate analysis was used to evaluate the presence of
associated variables. Signiﬁcance was deﬁned at the 0.05
level.
5. Results
The median in situ period untreated and silver-coated cathe-
ters were 138.9 (range, 1–1,845) and 115.0 (range, 4–1,348)
days, respectively, (P = 0.653). Calculating the in situ times
after classiﬁcation for diﬀerent age groups, it will be overt,4 International Journal of Nephrology
Table 2: Indications for the insertion of large-bore catheters (n = 159).
Indications (n)%
Renal failure
Acute kidney injury (AKI) 40 25.2
Clotting ﬁstula 34 21.4
Septicemia (catheter-related) 29 18.2
Abscess (catheter-related) 8 5.0
Bleeding (catheter-related) 4 2.5
Catheter thrombosis and faults in catheter material 23 14.5
Hypercholesterolemia
LDL-apheresis 10 6.3
Septicemia 2 1.24
Plasmapheresis
Diﬀerent indications 6 3.8
Removal by patient 1 0.62
Carcinoma
Removal by patient 2 1.24
Table 3: Microbiological examinations of 105 untreated and 54
surface-treated catheters.
Microorganisms Untreated (n) % Treated (n)%P value
Negative 47 45 26 48 n.s.
S. aureus 31 29 21 38 n.s.
S. epidermidis 7 712 n . s .
Pseudomonas 1 1 0 0 n.s.
E n t e r o b a c t e r 1 112 n . s .
Others 18 17 5 10 n.s.
that in patients older than 45 years, in situ times were sig-
niﬁcantly longer (P<0.01) (Figure 1). Comparing the in
situ times of untreated catheters after classiﬁcation for in situ
times, there was a tendency towards longer in situ times for
the silver-coated catheters (Figure 2). In the median, cathe-
ters were used for 44 (range, 1–670) treatment sessions. Un-
treated catheters were used for 51 (range, 1–625) treatments,
silver-coated catheters for 39.0 (range, 1–670, P = 0.849)
treatment sessions.
Performing microbiologic examinations, some diﬀer-
ences were overt. Of the untreated catheters tips, 55% cul-
tured positive for bacteria. Of the cultures in patients with
surface-treatedcatheters,52%werepositive,notsigniﬁcantly
lower.Althoughuntreatedcathetersshowedalowerinfection
ratewithStaphylococcusaureus,intreatedcatheterstheinfec-
tion rate with Staphylococcus epidermidis, pseudomonas, and
others such as saprophytes were not signiﬁcantly lower
(Table 3).
Performingmultivariateanalysis,therewasastrongasso-
ciation between catheters’ in situ period (R-square = 0.96),
the number of treatment sessions (β = 0.97, P<0.001), and
patients’ age (β = 0.095, P = 0.002). There was no associ-
ation between the in situ time and silver-coated/untreated
catheters, results of the bacteriological examination, and pa-
tients diagnosis or outcome. Catheter malfunction or ﬁbrin
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Figure 1:Insitutimesoftreatedanduntreatedcathetersinpatients
after classiﬁcation and age.
sheath formation as an outcome of both groups was not
investigated.
The decrease of the infection rate in surface-treated
catheterinthepreliminarystudyfrom2001cannotbeseenin
thispresentedstudyfrom1992to2007.Anexplanationcould
be that all and more available data are now evaluated. The
untreated catheters showed a higher positive culture for bac-
teria of 55% versus 52% to surface-treated catheters, but
without signiﬁcance. The procedure for both studies was the
same.
6. Discussion
Catheter-related bacteremia and thrombosis are the most
dangerous complications of large-bore catheter aside fromInternational Journal of Nephrology 5
45
40
35
30
30
38
32
26
41
33
25
20
15
10
5
0
Untreated catheters
In situ period (days)
Treated catheters
 
(
%
)
<51
>200
51–200
Figure 2: In situ periods of untreated and silver-coated catheters
after classiﬁcation for in situ times.
accidentalpunctureofanartery.Thesecatheter-relatedcom-
plications are contributing factors to increasing cost med-
ical care. They are responsible for patient discomfort, mor-
bidity, and occasional mortality. In addition to colonization,
biocompatibility of a catheter material is an important con-
tributing factor to a successful clinical outcome, particularly
in catheters that remain in situ for several weeks or months.
Though improved since the use of centrally placed catheters,
the incidence of catheter clotting was previously very high.
Infectionratesrangefrom5to30%andthemostbacteria
foundistheStaphylococcusaureus.Theseratesdonotdepend
on the route of vascular access [39, 40]. Catheter-related
Staphylococcus aureus bacteremia is one of the main causes of
morbidity and a preventable cause of death in hemodialysis.
Patients on dialysis are at a high risk of Staphylococcus aureus
bacteremia,andtheyhaveafourtimes highermortalityfrom
central venous catheter-related Staphylococcus aureus bacter-
emia than other patients [14, 41, 42]. As such, new surgical
techniques, catheter materials, and therapeutic drugs, and
sterile handling during the treatments that inﬂuence perfor-
mance and longevity of catheters are of great interest to the
medical community [43, 44].
These catheter-related complications are contributing
factors to the increasing cost of medical care. They are res-
ponsibleforpatientreadmissionsandlongerhospitalstaysas
well as patients discomfort, morbidity, and occasional mor-
tality. Feldman et al. calculated in 1996, the costs of the mor-
bidity due to catheter infections will soon exceed $1 billion
p e ry e a r[ 45]. Therefore, he demanded to reduce vascular-
access-related morbidity and that strategies must be devel-
oped not only to prevent and detect appropriately early syn-
thetic vascular access dysfunction, but to better identify the
patients in a whom radial arteriovenous ﬁstula is a viable cli-
nical option. Table 4 shows representative health care cost
savings for hemodialysis catheters, given speciﬁc infection
rates and potential infection rate reductions achieved by
treated catheters [35]. The cost analysis was calculated using
Table 4:Potentialhealthcarecostreductionsthatcouldbeachieved
through the use of surface-treated catheters [45].
Device Hemodialysis Average
infection (%)
Annual usage (devices) 125,971
Infection rate (%) 5–20 Rate: 12
Cost ($) of complication
(due to infection) 3.517
Cost ($) of coating 12
Reduction of infections (%) 10–65 Reduction 40
Market size (1997) ($) 12.6 million
Price ($) of each device
(surface treatment) 120
Savings ($) per year by using
surface-treated devices 17.7 milion Reduction 40
the literature and the available costs of diﬀerent companies,
which distribute these catheters [46].
To reduce infection rates and thrombogenicity, coated
catheters and cuﬀsw e r ei n v e s t i g a t e d[ 47–52]. The clinical
results of our preliminary investigations showed a signiﬁcan-
tly reduced infection rate in treated versus untreated cathe-
ters, a reduction of more than 75% [28]. With the silver sur-
face treatment, a very smooth metallic surface was obtained,
which was responsible for a lower thrombogenicity rate. The
activation of coagulation factors at the catheter surfaces was
not investigated. Silver ions are bactericidal, therefore, no
bacteria growth is possible on the treated catheter surface.
Thepositiveassociationbetweentheinsitutimeofthecathe-
ters and the patients’ age maybe because of an alteration of
the immune system in elderly patients, especially in hemo-
dialysis patients.
But in our retrospective study of all silver-coated cathe-
ters no signiﬁcant reduction in infection rate, improvement,
or life expectancy of silver-coated versus untreated catheters,
which were inserted during 1992–2007, was observed. One
reason can be that with the IBAD technology, only the outer
surface is coated with silver. The postulated penetration of
silver ions from the outer to the inner surface cannot be
shown with these results. The only outer-surface-treated
catheters with silver have no advantage in point of view of
reducing infection rate and improvement of patients versus
the untreated catheters. The handling of the catheters before,
during, and after the extracorporeal treatments cannot pre-
vent the contamination with bacteria, especially the untrea-
ted inner side.
Based on these results, new materials must be developed,
which should have better biocompatibility to reduce side ef-
fects so that they can be left in situ for a long time, because
the part of dialysis in patients with vascular problems is
increasing in the last decade, because the age of HD patients
is permanently growing up. As the requirement for more and
more artiﬁcial organs and/or organ replacements increases,
especially in elderly patients, there will be a deﬁnite need
for new materials with better biocompatibility and for sui-
table technologies to solve these infection, thrombosis, and6 International Journal of Nephrology
medical problems to reduce the costs and get a better impro-
vement of patients.
This requirement shows perhaps the new developed
catheter material, the microdomain-structured surface
(PUR-SMA-coated catheters, Gambro, Germany) [28]. Mic-
rodomain surfaces are considered the most biocompatible
because they mimic the structure of natural biological sur-
faces. Microdomain structures are used to match the mul-
tiple requirements for improved catheter surfaces, that is
reduced thrombogenicity and improved antimicrobial prop-
erties. An SMA-modiﬁed polyurethane coating consists of
hydrophobic and hydrophilic microdomains in range below
50nm. Up to 50 percent of the SMA molecule is presented to
the surface and creates microdomain structures surfaces. If
the domains are below a critical dimension of approximately
100nmm, theoretical considerations indicate that interac-
tion with proteins, blood cells, or even bacteria will be unsta-
ble and therefore, not occur as frequently as on non-micro-
domain structured surfaces.
The new PUR-SMA coating prevents contact of blood
componentswithbariumsulfate,possiblyleadingtoleaching
as particles or dissolving in the surrounding media. The ad-
vantage of the PUR-SMA surface treatment is the coating of
the inner and the outer surface in contrast to the ion-
beam-based surface treatment technologies in which can be
treated only the outer surface of the catheters. The prelimi-
nary results with these PUR-SMA-coated catheters showed
a good biocompatibility without any blood deposits and a
low thrombogenicity and coagulation activity. The microbi-
ological results were low and of those from the Spi-Argent
catheters [53].
More new materials must be developed, which should
have better biocompatibility to reduce side eﬀects so that
they can be left in situ for a long time, because the part of
dialysisinpatientswithvascularproblemsisincreasinginthe
last decade. As the requirement for more and more artiﬁcial
organs and/or organ replacements increases, there will be a
deﬁnite need for new materials with better biocompatibility
and for suitable technologies to solve these infection, throm-
bosis, and medical problems to reduce the costs and get a
better improvement of patients. But it appears impossible
to create a surface with an absolute “zero” adherence due to
thermodynamical reasons and due to the fact that a modiﬁed
materialsurfaceisinvivorapidlycoveredbyplasmaandcon-
nective tissue proteins.
Therefore, other concepts of the prevention of implant-
associated infections must involve the impregnation of the
devices in the inner and outer surface with antibiotics, anti-
microbial substances, and/or metals [54]. Another point is
to understand the processes leading to the development of
catheter-related bacteremia in order to oﬀer eﬀective preven-
tative and therapeutic possibilities [55].
7. Conclusion
In a retrospective study from 1992 to 2007, outer-surface-
treated catheters with silver versus untreated catheters in 159
patients,whoneededalarge-borecatheter,wereinvestigated.
The results of a preliminary study from 2001, which showed
75% decline in the infection rate with the surface-treated
catheters, cannot be conﬁrmed with the presented study.
There was no association between the in situ time and silver-
coated/uncoated catheters, results of the bacteriological exa-
mination, and patients diagnosis or outcome. One reason
maybe that in the surface-treated catheters only the outer
surfacewascoatedwithsilverandanotherreasonisthepossi-
bility of contamination by the handling during the extra-
corporeal treatments. Therefore, new materials and surface
treatment technologies are needed to save health care costs
for hemoldiaysis catheters, to reduce infection rates and
thrombus formations and help to improve the patients out-
come.
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